A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia
Acute myeloid leukemia with biallelic mutation of CEBPA (CEBPA-dm AML) is a distinct
good prognosis entity recognized by WHO 2016 classification. However, testing for CEBPA …
good prognosis entity recognized by WHO 2016 classification. However, testing for CEBPA …
Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia
O Fuster, E Barragán, P Bolufer, E Such, A Valencia… - Annals of …, 2012 - Springer
During last years, molecular markers have been increased as prognostic factors routinely
screened in acute myeloid leukemia (AML). Recently, an increasing interest has been …
screened in acute myeloid leukemia (AML). Recently, an increasing interest has been …
Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical …
A Dufour, F Schneider, KH Metzeler… - Journal of clinical …, 2010 - ascopubs.org
Purpose CEBPA mutations are found as either biallelic (bi CEBPA) or monoallelic (mo
CEBPA). We set out to explore whether the kind of CEBPA mutation is of prognostic …
CEBPA). We set out to explore whether the kind of CEBPA mutation is of prognostic …
Double, but not single, CEBPA mutations define a subgroup of acute myeloid leukemia with favorable outcome and a distinct gene expression profile
BJ Wouters, CAJ Erpelinck-Verschueren, B Lowenberg… - Blood, 2008 - Elsevier
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by various
cytogenetic and molecular abnormalities, some of which can be used as prognostic markers …
cytogenetic and molecular abnormalities, some of which can be used as prognostic markers …
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)
C Preudhomme, C Sagot, N Boissel… - Blood, The Journal …, 2002 - ashpublications.org
The transcription factor C/EBP α is crucial for differentiation of mature granulocytes.
Recently, different CEBPA gene mutations likely to induce differentiation arrest have been …
Recently, different CEBPA gene mutations likely to induce differentiation arrest have been …
CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis
MM Awad, DA Aladle, NK Abousamra… - …, 2013 - Taylor & Francis
Aim To assess the prognostic role of myeloid transcription factor gene CEBPA
(CCAAT/enhancer binding protein-α), a novel gene involved in leukemia in Egyptian adults …
(CCAAT/enhancer binding protein-α), a novel gene involved in leukemia in Egyptian adults …
Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta‐analysis
HY Li, DH Deng, Y Huang, FH Ye… - European journal of …, 2015 - Wiley Online Library
Objectives Increasing number of studies suggested that biallelic CEBPA (bi CEBPA)
mutations were associated with favorable prognosis in patients with acute myeloid leukemia …
mutations were associated with favorable prognosis in patients with acute myeloid leukemia …
Molecular Evaluation of CEBPA Gene Mutation in Normal Karyotype Acute Myeloid Leukemia: A Comparison of Two Methods and Report of Novel CEBPA Mutations …
F Ahmad, S Rajput, S Mandava… - Genetic Testing and …, 2012 - liebertpub.com
Background and Aim: Mutation in the CAAT/enhancer binding protein-α (CEBPA) gene has
been reported as being one of the common genetic abnormalities in acute myeloid leukemia …
been reported as being one of the common genetic abnormalities in acute myeloid leukemia …
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely …
BJ Wouters, B Löwenberg… - Blood, The Journal …, 2009 - ashpublications.org
Mutations in CCAAT/enhancer binding protein α (CEBPA) are seen in 5% to 14% of acute
myeloid leukemia (AML) and have been associated with a favorable clinical outcome. Most …
myeloid leukemia (AML) and have been associated with a favorable clinical outcome. Most …
Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients
A Dufour, F Schneider, E Hoster, T Benthaus… - Annals of …, 2012 - Springer
We and others have shown that cytogenetically normal (CN)-AML patients with biallelic
CEBPA gene mutations (bi CEBPA) represent a molecularly distinct group with a favorable …
CEBPA gene mutations (bi CEBPA) represent a molecularly distinct group with a favorable …